-- 週四,日本股市收低,受疲軟的工廠產出數據拖累,數據顯示中東緊張局勢加劇了經濟壓力。 日經225指數下跌1.06%,或632.54點,收在59,284.92點。 政府數據顯示,3月工業生產季減0.5%,低於先前1.1%的增幅預期,繼2月下降2.0%之後,連續第二個月出現下滑。 製造商預計4月產出將下降0.7%。疲軟的趨勢凸顯了日本央行面臨的挑戰,因為油價上漲推高了通膨,同時也給依賴進口的日本經濟帶來了壓力。 其他經濟新聞方面,3月零售額年增1.7%至14.3兆日圓,扭轉了先前0.1%的降幅,食品和飲料銷售的成長抵消了燃料銷售的下降。 企業方面,山一電子(TYO:6941)股價上漲4%,此前該公司已修復其菲律賓子公司在遭受勒索軟體攻擊後的系統,未造成營運或資料外洩影響。 Globe-ing(TYO:277A)股價下跌4%,此前該公司宣布將其在東京證券交易所的上市板塊從成長板塊調整至主機板市場。 東邦控股(TYO:8129)股價上漲3%,此前該公司表示將尋求股東批准,以啟動反收購機制,阻止3D Investment Partners的大規模股份收購。
Related Articles
Berenberg Adjusts Estimates for Galp Energia After 'Solid' Q1 Results; Hold Rating Maintained
Berenberg updated its earnings forecasts for Galp Energia (GALP.LS) after the Portuguese energy company reported its first-quarter results."Galp reported a solid set of results for Q126 on 27 April from an operational point of view, and beat consensus EBITDA expectations, although this was offset by some cash flow adjustments in the period. Delivery of the important Bacalhau project (Brazil) appears to be ahead of expectations, and, after a strong Q1 in the refining business, Galp is moving towards confirming the terms of its downstream merger with Moeve. In the earnings call, the company indicated that its 2026 guidance is now likely out of date given the macro backdrop, and that it may update its FY26 outlook in the Q2 results. We leave our Hold rating and EUR20 price target unchanged," the research firm said Wednesday.Against this backdrop, the research firm increased its 2026 EBITDA assumption by 3%, while cutting its cash flow from operations and free cash flow estimates by 4% and 3%, respectively, to account for a recent 320 million-euro renewable acquisition and other liquidity adjustments.Meanwhile, analysts maintained their share repurchase projection for 2026 at 250 million euros, while boosting their 2027 forecast to 455 million euros, which is 10% above consensus. Berenberg's EPS estimates for 2026 through 2028 were also revised upwards.
Henlius Biotech Doses First Patient in Lung Cancer Drug Trial in China
Shanghai Henlius Biotech (HKG:2696) dosed the first patient in a phase 1 clinical study of HLX3901 in mainland China, according to a Thursday Hong Kong bourse filing.The drug is being tested for the treatment of patients with advanced small-cell lung cancer or neuroendocrine carcinoma.
BP Confirms Preliminary Offshore Exploration Agreement With Venezuela
BP (BP.L) entered into a memorandum of understanding with the Bolivarian Republic of Venezuela to establish "potential areas for co‑operation in material offshore gas and future exploration," according to a statement sent toon Thursday.Venezuela's Acting President Delcy Rodríguez announced in a Wednesday signing event its offshore natural gas exploration deal with the British oil major, which covers the Deltana Platform, an oil and natural gas reservoir in the nation's eastern waters, according to a same-day report from Bloomberg News.BP Executive Vice President William Lin also said the company plans to launch a permanent regional office in Caracas, Venezuela.